P&G "Whistleblower" Raises Data Disclosure Issues
This article was originally published in The Pink Sheet Daily
Actonel clinical trial investigator Blumsohn claims that Procter & Gamble improperly withheld data from a study of the osteoporosis drug.
You may also be interested in...
A letter to OIG asks whether "administrative, regulatory, and/or legislative corrective actions in this area are needed."
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles